Jefferies on Aclaris Therapeutis (ACRS): 'We see this data building the foundation to support upward momentum'
Tweet Send to a Friend
Jefferies analyst Roger Song reiterated a Buy rating and $7.00 price target on Aclaris Therapeutis (NASDAQ: ACRS).The analyst comments "This ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
